Discover why Zymeworks Inc.'s innovative ADC pipeline and pivotal cancer drug data signal strong buy potential. Click for my ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma.

Off-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T-cell products may improve access to treatment versus autologous ones. We report the phase I experience of the allogeneic CD19 CAR ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout.

A 12-year-old girl with Bloom Syndrome, a rare genetic disorder, underwent T-cell receptor alpha beta depleted haploidentical bone marrow transplant (BMT) using stem cells from her younger brother at ...

Once the cause of her condition was discovered, the patient received a bone marrow stem cell transplant, to replace her dysfunctional T cells with healthy ones.